Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

[Imaging diagnosis of Alzheimer's disease].

Mänz C, Reimold M, Bender B, Bares R, Ernemann U, Horger M.

Rofo. 2012 Dec;184(12):1079-82. doi: 10.1055/s-0032-1319030. Epub 2012 Dec 4. Review. German. No abstract available.

PMID:
23212812
2.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

3.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

PMID:
21624562
4.

Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.

Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.

Brain. 2012 Jul;135(Pt 7):2115-25. doi: 10.1093/brain/aws113. Epub 2012 May 3.

5.

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.

Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN.

Ann Neurol. 2006 Jul;60(1):145-7.

PMID:
16802294
6.

Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.

Kemppainen NM, Aalto S, Karrasch M, Någren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO.

Ann Neurol. 2008 Jan;63(1):112-8.

PMID:
18023012
7.

Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.

Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, Någren K, Parkkola R, Rinne JO.

Arch Neurol. 2008 Apr;65(4):540-4. doi: 10.1001/archneur.65.4.540.

PMID:
18413480
8.

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Neurology. 2011 Mar 22;76(12):1085-90. doi: 10.1212/WNL.0b013e318212015e. Epub 2011 Feb 16.

PMID:
21325653
9.

Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G.

AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1030-6.

10.

[Brain functional imaging in Alzheimer's disease].

Ravasi L, Semah F.

Psychol Neuropsychiatr Vieil. 2009 Dec;7 Spec No 1:21-7. doi: 10.1684/pnv.2009.0193. Review. French.

PMID:
20061230
11.

Alzheimer's disease: spect and pet tracers for beta-amyloid imaging.

Valotassiou V, Archimandritis S, Sifakis N, Papatriantafyllou J, Georgoulias P.

Curr Alzheimer Res. 2010 Sep;7(6):477-86.

PMID:
20455860
12.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

13.

In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S.

Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):584-95.

PMID:
15545326
14.

Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex.

Kambe T, Motoi Y, Ishii K, Hattori N.

J Neurol. 2010 Mar;257(3):469-71. doi: 10.1007/s00415-009-5377-y. No abstract available.

PMID:
19915884
15.

Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.

Wang Y, Klunk WE, Debnath ML, Huang GF, Holt DP, Shao L, Mathis CA.

J Mol Neurosci. 2004;24(1):55-62.

PMID:
15314250
16.

Automated (11)C-PiB standardized uptake value ratio.

Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, Masters CL, Jones G, O'Keefe G, Salvado O, Ourselin S.

Acad Radiol. 2008 Nov;15(11):1376-89. doi: 10.1016/j.acra.2008.07.006.

PMID:
18995189
17.

[Novel neuroimaging perspectives in the diagnosis of dementia].

Jessen F.

Nervenarzt. 2008 Nov;79 Suppl 3:129-36; quiz 137. doi: 10.1007/s00115-008-2497-z. German.

PMID:
18830576
18.

MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review.

Minati L, Grisoli M, Bruzzone MG.

J Geriatr Psychiatry Neurol. 2007 Mar;20(1):3-21. Review.

PMID:
17341766
19.

Amyloid and its association with default network integrity in Alzheimer's disease.

Adriaanse SM, Sanz-Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Rombouts SA, Barkhof F, van Berckel BN.

Hum Brain Mapp. 2014 Mar;35(3):779-91. doi: 10.1002/hbm.22213. Epub 2012 Dec 14.

PMID:
23238869
20.

Functional imaging of visuospatial processing in Alzheimer's disease.

Prvulovic D, Hubl D, Sack AT, Melillo L, Maurer K, Frölich L, Lanfermann H, Zanella FE, Goebel R, Linden DE, Dierks T.

Neuroimage. 2002 Nov;17(3):1403-14.

PMID:
12414280
Items per page

Supplemental Content

Write to the Help Desk